ClinicalTrials.gg
CompletedNCT01344837Updated Aug 14, 2024

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

An observational study in Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer and Stage II Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Gynecologic Oncology Group · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
360
Sex
Female
01

Study summary

This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine whether synuclein-γ (SNCG) expression in primary tumor is associated with overall survival (OS) in uterine papillary serous carcinoma (UPSC) patients.

SECONDARY OBJECTIVES:

I. Determine whether SNCG expression is associated with clinical covariates (age at diagnosis, race, surgical stage, depth of myometrial invasion, presence of lymph vascular space invasion, lymph node status, location of extrauterine disease, chemotherapy, and radiation therapy) in UPSC patients.

II. Determine whether SNCG expression is associated with other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 in primary tumor tissue.

III. Determine whether SNCG expression is associated with progression-free survival (PFS).

IV. Determine whether SNCG expression is associated with synchronous or metachronous breast cancers.

EXPLORATORY OBJECTIVES:

I. Determine whether SNCG can be detected in sera from UPSC patients. II. Determine whether serum SNCG in UPSC patients differs from that in normal healthy control women and women with endometrioid endometrial cancer.

III. Determine whether serum SNCG in UPSC patients is associated with overall survival (OS), clinical covariates (listed above), tumor expression of biomarkers (listed above), PFS, and synchronous or metachronous breast cancers.

IV. Develop prediction models with a panel of biomarkers and clinical prognostic factors for OS, PFS, and synchronous or metachronous breast cancers in UPSC patients.

OUTLINE:

Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).

02

Conditions studied

  • Endometrial Serous Adenocarcinoma
  • Stage I Uterine Corpus Cancer
  • Stage II Uterine Corpus Cancer
  • Stage III Uterine Corpus Cancer
  • Stage IV Uterine Corpus Cancer
03

In context

Lead sponsor

Gynecologic Oncology Group is the lead sponsor of 188 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with uterine cancer

Eligibility criteria

Inclusion Criteria:

  • Women with uterine papillary serous carcinoma (UPSC) who were eligible for GOG-0210 protocol, a molecular staging study in endometrial cancer, or GOG-0136, a general specimen banking study for gynecologic cancer, have consented to future research, have -confirmed UPSC of any stage, and have satisfactory formalin-fixed and paraffin-embedded primary tumor with or without a satisfactory pre-operative serum specimen available for testing
  • Women with endometrioid endometrial cancer who were eligible for GOG-0210 or GOG-0136, have consented to future research, have histologically-confirmed endometrioid endometrial carcinoma with a similar stage, age and race/ethnicity distribution as the UPSC patients, have satisfactory formalin-fixed and paraffin-embedded primary tumor and/or pre-operative serum specimen available for testing
  • Normal healthy control women who participated in the Biopathology protocol for banking sera from normal healthy control women, have consented to future research, do not have a cancer or a history of cancer and have a similar age and race/ethnicity distribution as the UPSC patients and have satisfactory serum available for testing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
360 participants (actual)

Groups and cohorts

  • Observational

    Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).

    Other: Diagnostic Laboratory Biomarker Analysis · Other: Immunohistochemistry Staining Method · Other: Medical Chart Review · Genetic: Microarray Analysis · Other: Study of Socioeconomic and Demographic Variables · Genetic: Western Blotting

Interventions

  • OtherDiagnostic Laboratory Biomarker Analysis

    Correlative studies

  • OtherImmunohistochemistry Staining Method

    Correlative studies

    Also known as: Cell/Tissue, Immunohistochemistry, IHC, Immunohistochemistry

  • OtherMedical Chart Review

    Correlative studies

    Also known as: Chart Review

  • GeneticMicroarray Analysis

    Correlative studies

    Also known as: gene expression profile, Gene Expression Profiling, Microarray Technology, Microarray-Based Analysis

  • OtherStudy of Socioeconomic and Demographic Variables

    Correlative studies

  • GeneticWestern Blotting

    Correlative studies

    Also known as: Blotting, Western, WESTERN BLOT

06

What researchers measure

Primary outcomes

  1. Overall survival

    Kaplan-Meier survival curves for the overall survival (OS) endpoint will be generated separately for the three SNCG expression groups and globally compared using a log-rank test.

    Time frame: From time of entry onto GOG-0210, assessed up to 2 years

Secondary outcomes

  1. Presence of synchronous or metachronous breast cancer

    Cox proportional hazards models with dummy variable coding of the SNCG expression groups will be used to estimate hazard ratios, with tests of interaction with time and log-log plots used to evaluate the proportional hazards assumption. Sensitivity of the estimated hazard ratios to adjustment for other variables will be explored in the analyses for the Secondary Objectives.

    Time frame: Up to 2 years

  2. Progression-free survival

    Median survival times and 95% confidence intervals will be estimated from the Kaplan-Meier curves using Greenwood's formula for variance estimation.

    Time frame: From time of entry onto GOG-0210 to time of progression, assessed up to 2 years

07

Study locations

1 site
  • Gynecologic Oncology Group
    Philadelphia, Pennsylvania 19103, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in Jan 2018, 96 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2011
First posted
Apr 29, 2011
StartActual
Jan 2010
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01344837
Responsible party
Sponsor
First posted
Apr 29, 2011
Start date
Jan 2010
Primary completion
Jan 2018
Completion
Jan 2018
Last update
Aug 14, 2024

Study contacts

Barbara Buttin
principal investigator · Gynecologic Oncology Group
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion